BACKGROUND: Recent studies suggest poor sleep quality in patients with idiopathic pulmonary fibrosis (IPF). However, so far, the impact of IPF-related sleep breathing disorders (SBDs) on survival has not been extensively studied. METHODS: In a cohort of 31 (24 males) treatment-naïve, newly diagnosed consecutive IPF patients, we prospectively investigated the relationship of SBD parameters such as apnea-hypopnea index (AHI), maximal difference in oxygen saturation between wakefulness and sleep (maxdiff SpO2), and lowest sleep oxygen saturation (lowest SpO2) with clinical (survival, dyspnea, daytime sleepiness), pulmonary function, submaximal (6-min walk test [6MWT]) and maximal exercise variables (cardiopulmonary exercise test [CPET]), and right ventricular systolic pressure (RVSP). RESULTS: Sleep oxygen desaturation exceeded significantly that of maximal exercise (p < 0.001). Maxdiff SpO2 was inversely related to survival, DLCO%, and SpO2 after 6MWT, and directly with dyspnea, AHI, and RVSP. The lowest SpO2 was directly related to survival and to functional (TLC%, DLCO%) as well as submaximal and maximal exercise variables (6MWT distance, SpO2 after 6MWT, peak oxygen consumption/kg, SpO2 at peak exercise), while an inverse association with dyspnea score, AHI, and RVSP was observed. CONCLUSIONS: Our findings provide evidence that intermittent sleep oxygen desaturation significantly exceeds that of maximal exercise and is associated with survival in IPF patients. Furthermore, they imply the existence of a link between lung damage and apnea events resulting to the induction and severity of intermittent sleep oxygen desaturation that aggravate pulmonary arterial hypertension and influence IPF survival.
BACKGROUND: Recent studies suggest poor sleep quality in patients with idiopathic pulmonary fibrosis (IPF). However, so far, the impact of IPF-related sleep breathing disorders (SBDs) on survival has not been extensively studied. METHODS: In a cohort of 31 (24 males) treatment-naïve, newly diagnosed consecutive IPF patients, we prospectively investigated the relationship of SBD parameters such as apnea-hypopnea index (AHI), maximal difference in oxygen saturation between wakefulness and sleep (maxdiff SpO2), and lowest sleep oxygen saturation (lowest SpO2) with clinical (survival, dyspnea, daytime sleepiness), pulmonary function, submaximal (6-min walk test [6MWT]) and maximal exercise variables (cardiopulmonary exercise test [CPET]), and right ventricular systolic pressure (RVSP). RESULTS: Sleep oxygen desaturation exceeded significantly that of maximal exercise (p < 0.001). Maxdiff SpO2 was inversely related to survival, DLCO%, and SpO2 after 6MWT, and directly with dyspnea, AHI, and RVSP. The lowest SpO2 was directly related to survival and to functional (TLC%, DLCO%) as well as submaximal and maximal exercise variables (6MWT distance, SpO2 after 6MWT, peak oxygen consumption/kg, SpO2 at peak exercise), while an inverse association with dyspnea score, AHI, and RVSP was observed. CONCLUSIONS: Our findings provide evidence that intermittent sleep oxygen desaturation significantly exceeds that of maximal exercise and is associated with survival in IPF patients. Furthermore, they imply the existence of a link between lung damage and apnea events resulting to the induction and severity of intermittent sleep oxygen desaturation that aggravate pulmonary arterial hypertension and influence IPF survival.
Authors: Micah R Fisher; Paul R Forfia; Elzbieta Chamera; Traci Housten-Harris; Hunter C Champion; Reda E Girgis; Mary C Corretti; Paul M Hassoun Journal: Am J Respir Crit Care Med Date: 2009-01-22 Impact factor: 21.405
Authors: Lisa H Lancaster; Wendi R Mason; James A Parnell; Todd W Rice; James E Loyd; Aaron P Milstone; Harold R Collard; Beth A Malow Journal: Chest Date: 2009-06-30 Impact factor: 9.410
Authors: Kevin R Flaherty; Adin-Cristian Andrei; Susan Murray; Chris Fraley; Thomas V Colby; William D Travis; Vibha Lama; Ella A Kazerooni; Barry H Gross; Galen B Toews; Fernando J Martinez Journal: Am J Respir Crit Care Med Date: 2006-07-06 Impact factor: 21.405
Authors: T Przybyłowski; P Bielicki; M Kumor; K Hildebrand; M Maskey-Warzechowska; P Korczyński; R Chazan Journal: J Physiol Pharmacol Date: 2007-11 Impact factor: 3.011
Authors: P Lévy; J-L Pépin; C Arnaud; R Tamisier; J-C Borel; M Dematteis; D Godin-Ribuot; C Ribuot Journal: Eur Respir J Date: 2008-10 Impact factor: 16.671
Authors: Vidya Krishnan; Meredith C McCormack; Stephen C Mathai; Shikhar Agarwal; Brittany Richardson; Maureen R Horton; Albert J Polito; Nancy A Collop; Sonye K Danoff Journal: Chest Date: 2008-07-14 Impact factor: 9.410
Authors: A Karakatsani; D Papakosta; A Rapti; K M Antoniou; M Dimadi; A Markopoulou; P Latsi; V Polychronopoulos; G Birba; Labrakis Ch; D Bouros Journal: Respir Med Date: 2009-04-03 Impact factor: 3.415
Authors: Jingjing Liang; Brian E Cade; Karen Y He; Heming Wang; Jiwon Lee; Tamar Sofer; Stephanie Williams; Ruitong Li; Han Chen; Daniel J Gottlieb; Daniel S Evans; Xiuqing Guo; Sina A Gharib; Lauren Hale; David R Hillman; Pamela L Lutsey; Sutapa Mukherjee; Heather M Ochs-Balcom; Lyle J Palmer; Jessica Rhodes; Shaun Purcell; Sanjay R Patel; Richa Saxena; Katie L Stone; Weihong Tang; Gregory J Tranah; Eric Boerwinkle; Xihong Lin; Yongmei Liu; Bruce M Psaty; Ramachandran S Vasan; Michael H Cho; Ani Manichaikul; Edwin K Silverman; R Graham Barr; Stephen S Rich; Jerome I Rotter; James G Wilson; Susan Redline; Xiaofeng Zhu Journal: Am J Hum Genet Date: 2019-10-24 Impact factor: 11.025
Authors: Jessica B Snow; Charles E Norton; Michelle A Sands; Laura Weise-Cross; Simin Yan; Lindsay M Herbert; Joshua R Sheak; Laura V Gonzalez Bosc; Benjimen R Walker; Nancy L Kanagy; Nikki L Jernigan; Thomas C Resta Journal: Am J Respir Cell Mol Biol Date: 2020-06 Impact factor: 6.914